Insider Selling: IDEXX Laboratories (NASDAQ:IDXX) EVP Sells 11,345 Shares of Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP George Fennell sold 11,345 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total value of $7,337,038.40. Following the transaction, the executive vice president owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock traded up $2.20 during mid-day trading on Wednesday, hitting $648.73. 400,128 shares of the company’s stock traded hands, compared to its average volume of 516,144. The firm has a 50 day moving average price of $690.23 and a 200 day moving average price of $667.06. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The company has a market cap of $51.80 billion, a PE ratio of 49.64, a price-to-earnings-growth ratio of 3.89 and a beta of 1.67. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.15. The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

IDXX has been the subject of a number of research analyst reports. UBS Group reduced their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. BTIG Research dropped their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Morgan Stanley increased their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a research report on Monday, November 3rd. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Virtus Advisers LLC acquired a new position in shares of IDEXX Laboratories in the 3rd quarter valued at about $26,000. Park Place Capital Corp purchased a new position in IDEXX Laboratories during the fourth quarter valued at approximately $29,000. WealthCollab LLC acquired a new position in IDEXX Laboratories in the 2nd quarter valued at approximately $30,000. J.Safra Asset Management Corp purchased a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $31,000. Finally, Armstrong Advisory Group Inc. lifted its position in IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after buying an additional 19 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.